Eric Lefkofsky Discovers the Element Missing in the Data-Centric Approach to Cancer

Eric is a committed researcher who seeks to identify the cause of cancer, as well as ideal treatments for the condition. From his research, he found out that data is an essential for successful cancer treatment. The CEO and co-founder of Tempus says that there are several reasons for which patient data is a critical requirement. On acquiring it, the specialists are to integrate the genomic data with therapeutic statistics. Eric explains that patient data is not an issue, as there are ways of finding them. However, there is a loophole in bridging the gap. Combining the genomic and therapeutic data forms the major challenges affecting implementation of results. Molecular statistics could not be an issue, but then clinical data is also necessary.

Details Relating to Eric’s Tempus Organization

Mr Eric co-founded Tempus with the aim of allowing a platform to learn more about cancer therapies. Their primary objective is to develop databases to fine-tune cancer treatments. Eric combines his vast knowledge with the experience he has garnered over the years in making crucial decisions. He co-works with other scientists seeking to pursue the same cause as his. In his initiatives, Eric encourages the clinicians to record the details about their patients. He got motivated to launch the startup after being convicted of improving the healthcare sector, and particularly in the area relating to cancer. So far, the tech firm has created an operating system to enhance the fight against cancer.

Eric’s Commitment to Philanthropic Causes

Lefkofsky is a kindhearted man who seeks to support the community. He and his wife, Liz, founded Lefkofsky Family Foundation, a private philanthropic foundation. Their main aim was to boost initiatives that immensely impact people’s lives. There are several other places where Eric’s finances are channeled. Among them include The Museum of Science and Industry, the Art Institute of Chicago, as well as the Lurie Children’s Hospital of Chicago, where he serves as a Trustee. The entire healthcare sector takes pride in the innovation of Eric. With the prevailing trends, he is an amazing figure who will bring transformation in the world.

http://www.chicagobusiness.com/article/20161001/ISSUE01/310019995/can-eric-lefkofsky-save-your-life

Tempus’ Eric Lefofsky Works for Cancer Patients

Tempus is a company that has been able to help people who have gone through a cancer diagnosis. They have worked hard to make sure that things are working for the families of the people and have even been able to make sure that things are going the right way for them. It is something that has given Eric Lefofsky the chance to make sure that they are getting what they can out of different things. Because of the way that Mr Lefofsky has done what he can about the different aspects of cancer, he is able to help people out while their lives are being turned over by cancer. He also works with a geneticist who is able to come up with actual cures for cancer. Together, they are Tempus. The company is something that he felt was necessary after a personal experience with cancer and the devastating consequences of it.

While he was in retirement from the money that he made off of Groupon, Eric Lefofsky was able to do a lot of things but the majority of things that he did paled in comparison to the troubles that his wife had to deal with. For example, their life was tumultuous while she was undergoing treatment. Eric Lefofsky was able to stay home with his wife and take care of her but he knew that many people who were related to those who had cancer. He hoped that things could be made better for the families who had to deal with cancer.

That is where the idea for Tempus came about. Eric was already confident in the skills that he had with building businesses and making sure that they were suitable for all people. He took the principles that he used with Groupon and applied them to the ideas of Tempus. While the company has not had the chance to be in business for as long as what Groupon has been, it has been nearly as successful. The best part of it for Eric Lefofsky is that he is able to actually help people out with this type of business.

Eric Lefofsky on Twitter.

Dr. Clay Siegall & His Significant Presence In Cancer Research

 

Cancer is one of the most prevalent diseases in society today as well as in history. This illness can manifest within the human body in a number of different organs. Just about everyone has been affected by this devastating disease in some form or another, but over the past 16 years, the fight against cancer is looking much more promising thanks to breakthrough therapies. Seattle Genetics is one of the leading organizations that specialize in the development and commercialization of these advanced therapies. Since it’s inception back in 1998, the organization has grown dramatically into the powerhouse of today. There are more than 800 employees under it’s huge umbrella and Seattle Genetics produces some of the best cancer treatments in the world.

For any great company/business there has to be great leadership and Clay Siegall fits the bill perfectly. This guy is worth his weight in gold thanks to his broad educational background, persistence, and passion. Siegall is known by many as a man of many acts. He has the label of being an entrepreneur, investor, author, scientist, guest speaker, and doctor. His resume of success span over decades while working with GlaxoSmithKline, The National Cancer Institute, and The National Institute of Health. Thanks to Dr. Siegall, Seattle Genetics is the leading cancer research organization in the world as it’s stock prices has risen dramatically over half a decade. The guy is a natural philanthropist as well because he does everything in his power to save lives. Dr. Siegall has also raised $1.2 Billion through public and private funding.

As of 2016, Seattle Genetics has grown to be one of the fastest growing companies in the country, stated by Forbes. With the abundance of many newer drugs in it’s pipeline, the company will be looking to fill the void by hiring another 200 employees. All in all, this is the future of cancer research and Dr. Clay Siegall is stiring the pot of success.